Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Combining Enbrel and Celebrex

Although Immunex Corp. shares dropped $9.31 last Monday in the wake of the New Year's Eve approval of G.D.Searle & Co.'s Celebrex celecoxib, IMNX believes its Enbrel etanercept soluble TNF

Read the full 304 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE